Furthermore, inhibitors against CHK1 and BRD4 are currently trialed in combination with immunotherapies in patients with advanced solid tumors, including HCC (NCT04840589, NCT03059147, NCT03495323). Here, CHEK1 is linked to hepatocellular carcinoma.